LIQUID BIOPSY

 

 

Liquid biopsy presents an amazing chance to transform our health care from a reactive to a proactive system. With the help of AI and advanced analytics systems we are now able to perform non-invasive liquid biopsy procedures for regular monitoring of vulnerable patients whilst altering treatment pathways in real time to provide a more personalised approach to therapy reducing suffering and costs.

THIS YEAR’S WORLD LEADING LIQUID BIOPSY SPEAKERS

 

 

 

Liquid Biopsy, Tuesday 2 November 2021

10:40

Networking Break

Liquid Biopsy
11:35

Chair's Remarks

Liquid Biopsy
12:00

ThermoFisher

Liquid Biopsy
12:40

Beckman Coulter Life Science

13:20

Networking Lunch Break

Stephen Hague
Liquid Biopsy
15:00

Single Cell multiomics: insights into disease characterization.

Catherine Alix Panabieres
Liquid Biopsy
15:20

Circulating Tumor Cells as Liquid Biopsy: From Discovery to Clinical Application

  • How to detect and analyze single viable CTCs?
  • Clinical relevance of CTCs: the example of PD-L1 in Onco-immunology
  • Challenges to establish CTC lines from metastasis-competent CTCs in colon cancer
Liquid Biopsy
15:40

Bio-techne

16:20

Networking Break

Klaus Lindpaintner
Liquid Biopsy
17:00

Glycoproteomics-Based Liquid Biopsy Profiles as Powerful New Tool to Predict Checkpoint-Inhibitor Response and Select Optimal Drug Regimen

Yasmin Panchbhaya
Liquid Biopsy
17:20

Discover Optimized Purification Solutions for cfDNA and FFPE DNA/RNA Samples

Tina Han
Liquid Biopsy
17:40

How Twist Lead the Way in Target Enrichment for Liquid Biopsy

Twist Bioscience’s double-stranded DNA probes can be individually tuned to enrich target regions with exceptional uniformity, reducing the overall cost of sequencing. Twist’s fast and precise DNA synthesis platform allows iterative testing of custom panels before locking in the final design - all while still providing exceptional uniformity. Continuing to innovate, Twist now offers a faster solution to hybridization that allows researchers to move from sample to sequencer in a single day. Applications for detection of cancer biomarkers have been developed with cfDNA and differentially methylation regions. This presentation presents data that illustrate target enrichment efficiency through diverse sample qualities using Twist’s complete solution. The data will demonstrate how Twist enables researchers to sequence more deeply and more efficiently into each sample.
18:00

Neri & Sons Band & Networking Drinks Reception

last published: 19/Oct/21 21:45

Liquid Biopsy, Wednesday 3 November 2021

10:20

Networking Break + Speed Networking

13:00

Networking Lunch Break

16:00

Networking Break

18:00

Drinks Reception

last published: 19/Oct/21 21:45

Liquid Biopsy, Thursday 4 November 2021

last published: 19/Oct/21 21:45

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034